Stock CNTA CENTESSA PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
8.63 USD +6.28% Intraday chart for Centessa Pharmaceuticals plc +4.35% +8.42%
May. 31 Nxera Pharma to Receive $4.6 Million Milestone Payments From Centessa Pharmaceuticals MT
May. 13 Centessa Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Morgan Stanley Upgrades Centessa Pharmaceuticals to Equalweight From Underweight, Doubles Price Target to $8 From $4 on 'Encouraging' Preclinical Data on Narcolepsy Treatment Candidate
MT
Guggenheim Adjusts Price Target on Centessa Pharmaceuticals to $10 From $9, Maintains Buy Rating
MT
Goldman Sachs Adjusts Price Target on Centessa Pharmaceuticals to $5 From $4.50, Maintains Neutral Rating
MT
BMO Capital Adjusts Centessa Pharmaceuticals Price Target to $15 From $11, Maintains Outperform Rating
MT
Evercore ISI Initiates Centessa Pharmaceuticals at Outperform Rating
MT
Guggenheim Initiates Centessa Pharmaceuticals at Buy With $9 Price Target
MT
SVB Securities Initiates Centessa Pharmaceuticals at Outperform With $6 Price Target
MT
Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $4 From $5, Maintains Underweight Rating
MT
Morgan Stanley Double Downgrades Centessa Pharmaceuticals to Underweight From Overweight, Adjusts Price Target to $5 From $10
MT
BMO Capital Adjusts Centessa Pharmaceuticals' Price Target to $11 from $19, Keeps Outperform Rating
MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $4 From $5, Keeps Neutral Rating
MT
Morgan Stanley Adjusts Price Target for Centessa Pharmaceuticals to $10 From $15, Maintains Overweight Rating
MT
BMO Capital Starts Centessa Pharmaceuticals at Outperform With $19 Price Target
MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $8 from $12, Keeps Neutral Rating
MT
Morgan Stanley Adjusts Centessa Pharmaceuticals Price Target to $15 From $19, Maintains Overweight Rating
MT
Morgan Stanley Trims Centessa Pharmaceuticals Price Target to $19 From $20, Maintains Overweight Rating
MT
Goldman Sachs Starts Centessa Pharmaceuticals at Neutral, Maintains Price Target at $12
MT
Morgan Stanley Adjusts Centessa Pharmaceuticals' Price Target to $20 from $37, Keeps Overweight Rating
MT
CENTESSA PHARMACEUTICALS : Jefferies Starts Centessa Pharmaceuticals at Buy With $35 Price Target
MT
CENTESSA PHARMACEUTICALS : Morgan Stanley Starts Centessa Pharmaceuticals at Overweight With $37 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CNTA Stock
  4. News Centessa Pharmaceuticals plc
  5. Analyst Reco.